Novartis AG
(XSWX:NOVNEE)
CHF
94.01
0.77 (0.83%)
Market Cap: 191.63 Bil
Enterprise Value: 207.19 Bil
PE Ratio: 14.59
PB Ratio: 5.44
GF Score: 78/100 - Q1 2024 Novartis AG Earnings Call TranscriptApr 23, 2024CHF89.6 (+2.36%)Earnings
- Novartis AG Annual Shareholders Meeting TranscriptMar 05, 2024
- MorphoSys AG to be Acquired by Novartis AG Call TranscriptFeb 06, 2024
- Q4 2023 Novartis AG Earnings Call TranscriptJan 31, 2024CHF90.47 (-0.88%)Earnings
- Novartis AG at JPMorgan Healthcare Conference TranscriptJan 08, 2024
- Novartis AG R&D Day TranscriptNov 28, 2023
- Novartis AG Impact & Sustainability Annual Event TranscriptNov 13, 2023
- Q3 2023 Novartis AG Earnings Call TranscriptOct 24, 2023CHF85.06 (+0.31%)Earnings
- Novartis AG PSMAfore Data at ESMO Presentation TranscriptOct 24, 2023
- Q2 2023 Novartis AG Earnings Call TranscriptJul 18, 2023CHF85.59Earnings
- Novartis AG - Sandoz Capital Markets Day (UK) TranscriptJun 12, 2023
- Novartis AG - Sandoz Capital Markets Day (USA) TranscriptJun 08, 2023
- Novartis AG at ASCO Investor Meeting (Virtual) TranscriptJun 05, 2023
- Q1 2023 Novartis AG Earnings Call TranscriptApr 25, 2023CHF93.23 (+4.04%)Earnings
- Novartis AG Annual Shareholders Meeting TranscriptMar 07, 2023
- Q4 2022 Novartis AG Earnings Call TranscriptFeb 01, 2023CHF80.89 (-2.58%)Earnings
- Novartis AG at JPMorgan Healthcare Conference TranscriptJan 09, 2023
- Novartis AG to Discuss Iptacopan ASH Update TranscriptDec 13, 2022
- Novartis AG Investor Update on Access & Sustainability TranscriptNov 30, 2022
- Q3 2022 Novartis AG Earnings Presentation TranscriptOct 25, 2022
- Meet Novartis AG Management Investor Event TranscriptSep 22, 2022
- Novartis AG Announces Intention to Separate Sandoz Business to Create a Standalone Company Call TranscriptAug 25, 2022
- Novartis AG Announces Intention to Separate Sandoz Business to Create a Standalone Company Call - Media TranscriptAug 25, 2022
- Q2 2022 Novartis AG Earnings Call TranscriptJul 19, 2022CHF83.4 (+0.72%)Earnings
- Q1 2022 Novartis AG Earnings Call TranscriptApr 26, 2022CHF86.84 (+1.05%)Earnings
- Novartis AG New Organizational Model Investor Call TranscriptApr 04, 2022
- Novartis AG Annual Shareholders Meeting TranscriptMar 04, 2022
- Q4 2021 Novartis AG Earnings Call TranscriptFeb 02, 2022CHF78.72 (-3.27%)Earnings
- Novartis AG at JPMorgan Healthcare Conference (Virtual) TranscriptJan 10, 2022
- Novartis AG Leqvio® FDA Approval Investor Call TranscriptDec 23, 2021
- Novartis AG R&D Day (Virtual) TranscriptDec 02, 2021
- Novartis AG at Novartis Co-Creating Impact Summit (Virtual) - Morning Session TranscriptDec 02, 2021
- Novartis AG Webinar: Integrating ESG Into Strategy TranscriptNov 12, 2021
- Q3 2021 Novartis AG Earnings Call TranscriptOct 26, 2021CHF85.47Earnings
- Novartis AG ESG Investor Day TranscriptSep 30, 2021
- Q2 2021 Novartis AG Earnings Call TranscriptJul 21, 2021CHF85.47Earnings
- Novartis AG Iptacopan (LNP023) Update Call TranscriptJun 22, 2021
- Novartis AG Oncology Update Call TranscriptJun 08, 2021
- Novartis AG Cardiovascular Update Call TranscriptMay 18, 2021
- Q1 2021 Novartis AG Earnings Call TranscriptApr 27, 2021CHF81.79Earnings
- Novartis AG Annual Shareholders Meeting TranscriptMar 02, 2021
- Novartis AG at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 25, 2021
- Novartis AG to Discuss Entresto® FDA Label Expansion Investor Q&A Call TranscriptFeb 17, 2021
- Novartis AG Materiality Assessment Webinar: Dialogue Matters TranscriptFeb 08, 2021
- Q4 2020 Novartis AG Earnings Call TranscriptJan 26, 2021CHF83.58 (-3.39%)Earnings
- Novartis AG at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Novartis AG, ABN Amro Bank NV & BlackRock Inc at Novartis Co-Creating Impact Summit (Virtual) - PM Session TranscriptDec 09, 2020
- Novartis AG at Novartis Co-Creating Impact Summit (Virtual) - AM Session TranscriptDec 09, 2020
- Virtual Meet Novartis AG Management Investor Event TranscriptNov 24, 2020
- Q3 2020 Novartis AG Earnings Call TranscriptOct 27, 2020CHF76.77Earnings
- Novartis AG ESG Investor Event TranscriptSep 01, 2020
- Novartis AG to Discuss Kesimpta® FDA Approval Investor Call TranscriptAug 21, 2020
- Q2 2020 Novartis AG Earnings Call TranscriptJul 21, 2020CHF77.3Earnings
- Novartis AG to Discuss the Oncology Pipeline Update Call TranscriptJun 15, 2020
- Novartis AG at UBS Global Healthcare Conference (Virtual) TranscriptMay 20, 2020
- Q1 2020 Novartis AG Earnings Call TranscriptApr 28, 2020CHF77.3Earnings
- Novartis AG to Discuss Zolgensma® MDA Data Call TranscriptMar 30, 2020
- Novartis AG Annual Shareholders Meeting TranscriptFeb 28, 2020
- Q4 2019 Novartis AG Earnings Call TranscriptJan 29, 2020CHF86.1Earnings
- Salesforce.Com Inc, UnitedHealth Group Inc, Alphabet Inc, Color, and Novartis AG at JPMorgan Healthcare Conference Panel TranscriptJan 15, 2020
- Novartis AG at JPMorgan Healthcare Conference TranscriptJan 13, 2020
- Novartis AG R&D Day TranscriptDec 05, 2019
- Novartis AG to Acquire The Medicines Company for USD 9.7 Billion Call TranscriptNov 25, 2019
- Q3 2019 Novartis AG Earnings Call TranscriptOct 22, 2019CHF86.1Earnings
- Novartis AG to Discuss Beovu® FDA Approval Investor Call TranscriptOct 08, 2019
- Novartis AG to Discuss Kisqali® MONALEESA-3 ESMO Data Investor Call TranscriptOct 01, 2019
- Novartis AG to Discuss Ofatumumab (OMB157) ECTRIMS Data Investor Call TranscriptSep 16, 2019
- Novartis AG ESG Investor Event TranscriptSep 09, 2019
- Novartis AG to Discuss the Zolgensma® Update Call TranscriptAug 07, 2019
- Q2 2019 Novartis AG Earnings Call TranscriptJul 18, 2019CHF92.8 (+3.69%)Earnings
- Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call TranscriptMay 27, 2019
- Meet Novartis AG Management Investor Event - Breakout Sessions (Day 2) TranscriptMay 23, 2019
- Meet Novartis AG Management Investor Event - CEO Introduction (Day 2) TranscriptMay 23, 2019
- Novartis AG to Discuss Acquisition of Xiidra® from Takeda Pharmaceutical Co Ltd Call TranscriptMay 09, 2019
- Novartis AG to Discuss Zolgensma (AVXS-101) Clinical Data Call TranscriptMay 08, 2019
- Q1 2019 Novartis AG Earnings Call TranscriptApr 24, 2019CHF86.54Earnings
- Novartis AG at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean TranscriptApr 23, 2019
- Novartis AG Mayzent FDA Approval Investor Call TranscriptMar 27, 2019
- Novartis AG Annual Shareholders Meeting TranscriptFeb 28, 2019
Novartis AG PSMAfore Data at ESMO Presentation Transcript
Oct 24, 2023 / 11:00AM GMT
Release Date Price:
CHF85.06
(+0.31%)
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)